| 000 | 01663 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250518081649.0 | ||
| 264 | 0 | _c20210707 | |
| 008 | 202107s 0 0 eng d | ||
| 022 | _a1600-0641 | ||
| 024 | 7 |
_a10.1016/j.jhep.2019.09.025 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCheng, Ann-Lii | |
| 245 | 0 | 0 |
_aChallenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. _h[electronic resource] |
| 260 |
_bJournal of hepatology _c02 2020 |
||
| 300 |
_a307-319 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xtherapeutic use |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xblood |
| 650 | 0 | 4 |
_aCTLA-4 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xblood |
| 650 | 0 | 4 |
_aCombined Modality Therapy _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmune Checkpoint Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aImmunotherapy _xmethods |
| 650 | 0 | 4 |
_aLiver Neoplasms _xblood |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aProgression-Free Survival |
| 650 | 0 | 4 |
_aT-Lymphocytes _ximmunology |
| 700 | 1 | _aHsu, Chiun | |
| 700 | 1 | _aChan, Stephen L | |
| 700 | 1 | _aChoo, Su-Pin | |
| 700 | 1 | _aKudo, Masatoshi | |
| 773 | 0 |
_tJournal of hepatology _gvol. 72 _gno. 2 _gp. 307-319 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jhep.2019.09.025 _zAvailable from publisher's website |
| 999 |
_c30534942 _d30534942 |
||